The difference in one sentence
BPC-157 is a fifteen-amino-acid pentadecapeptide derived from gastric juice; KPV is a three-amino-acid tripeptide and the C-terminal fragment of α-MSH. They share a category, not a structure.
Origin and structure
BPC-157 is a partial sequence taken from a protective protein in human gastric juice. At fifteen amino acids it is a mid-sized peptide, supplied as a lyophilised powder.
KPV consists of lysine, proline and valine — hence the name. It is the final segment of α-MSH (alpha-melanocyte-stimulating hormone). That fragment lacks the pigmentation activity of the full hormone, which is precisely what makes it useful in research: one signalling route in isolation.
| Feature | BPC-157 | KPV |
|---|---|---|
| Length | 15 amino acids | 3 amino acids (Lys-Pro-Val) |
| Origin | Protective sequence from gastric juice | C-terminal fragment of α-MSH |
| Research focus | Tissue repair, angiogenesis (VEGFR2) | Inflammatory signalling, intracellular routes |
What the research addresses
Research into BPC-157 concentrates largely on tissue repair and angiogenesis, with the VEGFR2 route the most frequently described point of action.
Research into KPV addresses inflammatory signalling, with the literature looking mainly at intracellular routes rather than cell-surface receptor binding. That is a different research question, not a smaller version of the same one.
Why they get mentioned together
Both appear in overviews around repair and inflammation, and are consequently often presented as interchangeable. Structurally and mechanistically that does not hold: three amino acids against fifteen, a hormone fragment against a gastric-juice sequence.
What this article does not cover
No statements about efficacy, dosing, side effects or which is superior. Both products are supplied strictly for laboratory research.
View both peptides
See BPC-157 · KPV · BPC-157 vs TB-500
For in-vitro laboratory research only. Not for human consumption. Not medical advice.
Last updated: August 2026